A US-based national surveillance study for the susceptibility and epidemiology of <i>Clostridioides difficile</i> isolates with special reference to ridinilazole: 2020–2021
David R. Snydman(Tufts Medical Center), Esther Duperchy(Johns Hopkins Hospital), Laura A. McDermott(Tufts University), Dimitrios I. Bourdas(Johns Hopkins University), Seth T. Walk(Montana State University), Karen C. Carroll(Johns Hopkins University), Stuart Johnson(Loyola University Medical Center), Cheleste M. Thorpe(Tufts Medical Center), Chris Lancaster(Summit (United Kingdom)), Ellie J. C. Goldstein(IBM Research - Almaden), Kevin W. Garey(University of Houston), Audrey N. Schuetz(Mayo Clinic), Dale N. Gerding(Edward Hines, Jr. VA Hospital), Qīng Wáng(Beijing Technology and Business University), Linda Gluck(Johns Hopkins University)
Cited by 15
Related Papers
Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America
|Clinical Infectious Diseases|2016|3k
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
|Clinical Infectious Diseases|2017|2.7k
Executive Summary: Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2014|1.5k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k